Cirrhotic Cardiomyopathy

ABSTRACT

Liver cirrhosis is associated with several cardiovascular abnormalities. Despite an increased baseline cardiac output, cirrhotic patients have a suboptimal ventricular response to stress. This phenomenon is called cirrhotic cardiomyopathy. The pathogenesis of this syndrome is multifactorial and includes diminished β-adrenergic receptor signal transduction, cardiomyocyte cellular plasma membrane dysfunction, and increased activity or levels of cardiodepressant substances such as cytokines, endogenous cannabinoids, and nitric oxide. Although cirrhotic cardiomyopathy is usually clinically mild or silent, overt heart failure can be precipitated by stresses such as liver transplantation or transjugular intrahepatic portosystemic shunt insertion. Moreover, cirrhotic cardiomyopathy may play a role in the pathogenesis of hepatorenal syndrome. Treatment of this condition is mainly supportive. Orthotopic liver transplantation appears to improve or normalize the condition, generally after a period of several months.

KEYWORDS

Cirrhotic cardiomyopathy - cirrhosis - heart failure - QT interval - hyperdynamic circulation

REFERENCES

• 1 Kowalski H J, Abelmann W H. The cardiac output at rest in Laennec's cirrhosis.  J Clin Invest. 1953;  32 1025-1033
• 2 Abelmann W H, Kowalski H J, McNeely W F. The hemodynamic response to exercise in patients with Laennec's cirrhosis.  J Clin Invest. 1955;  34 690-695
• 3 Bayley T J, Segel N, Bishop J M. The circulatory changes in patients with cirrhosis of the liver at rest and during exercise.  Clin Sci. 1964;  26 227-235
• 4 Murray J F, Dawson A M, Sherlock S. Circulatory changes in chronic liver disease.  Am J Med. 1958;  24 358-367
• 5 Regan T J, Levinson G E, Oldewurtel H A, Frank M J, Weisse A B, Moschos C B. Ventricular function in noncardiacs with alcoholic fatty liver: role of ethanol in the production of cardiomyopathy.  J Clin Invest. 1969;  48 397-407
• 6 Gould L, Shariff M, Zahir M, Di Lieto M. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop.  J Clin Invest. 1969;  48 860-868
• 7 Limas C J, Guiha N H, Lekagul O, Cohn J N. Impaired left ventricular function in alcoholic cirrhosis with ascites: ineffectiveness of ouabain.  Circulation. 1974;  49 754-760
• 8 Caramelo C, Fernandez-Munoz D, Santos J C et al.. Effect of volume expansion on hemodynamics, capillary permeability and renal function in conscious, cirrhotic rats.  Hepatology. 1986;  6 129-134
• 9 Lee S S. Cardiac abnormalities in liver cirrhosis.  West J Med. 1989;  151 530-535
• 10 Ma Z, Lee S S. Cirrhotic cardiomyopathy: getting to the heart of the matter.  Hepatology. 1996;  24 451-459
• 11 Liu H, Lee S S. Cardiopulmonary dysfunction in cirrhosis.  J Gastroenterol Hepatol. 1999;  14 600-608
• 12 Blendis L, Wong F. Is there a cirrhotic cardiomyopathy?.  Am J Gastroenterol. 2000;  95 3026-3028
• 13 Moller S, Henriksen J H. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease.  Heart. 2002;  87 9-15
• 14 Baik S K, Lee S S. Cirrhotic cardiomyopathy: causes and consequences.  J Gastroenterol Hepatol. 2004;  19(suppl 1) S185-S190
• 15 Kelbaek H, Eriksen J, Brynjolf I et al.. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver.  Am J Cardiol. 1984;  54 852-855
• 16 Grose R D, Nolan J, Dillon J F et al.. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis.  J Hepatol. 1995;  22 326-332
• 17 Bernardi M, Trevisani F, Santini C et al.. Plasma norepinephrine, weak neurotransmitters, and renin activity during active tilting in liver cirrhosis: relationship with cardiovascular homeostasis and renal function.  Hepatology. 1983;  3 56-64
• 18 Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis.  Gut. 2001;  49 268-275
• 19 Lunzer M R, Newman S P, Bernard A G, Manghani K K, Sherlock S P, Ginsburg J. Impaired cardiovascular responsiveness in liver disease.  Lancet. 1975;  2 382-385
• 20 Decaux G, Cauchie P, Soupart A, Kruger M, Delwiche F. Role of vagal neuropathy in the hyponatraemia of alcoholic cirrhosis.  Br Med J (Clin Res Ed). 1986;  293 1534-1536
• 21 Lee S S, Hadengue A, Moreau R, Sayegh R, Hillon P, Lebrec D. Postprandial hemodynamic responses in patients with cirrhosis.  Hepatology. 1988;  8 647-651
• 22 Mashford M L, Mahon W A, Chalmers T C. Studies of the cardiovascular system in the hypotension of liver failure.  N Engl J Med. 1962;  267 1071-1074
• 23 Mikulic E, Muñoz C, Puntoni L E, Lebrec D. Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis.  Clin Pharmacol Ther. 1983;  34 56-59
• 24 Ramond M J, Comoy E, Lebrec D. Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity.  Br J Clin Pharmacol. 1986;  21 191-196
• 25 Finucci G, Desideri A, Sacerdoti D et al.. Left ventricular diastolic function in liver cirrhosis.  Scand J Gastroenterol. 1996;  31 279-284
• 26 Galderisi M, Dini F L, Temporelli P L, Colonna P, de Simone G. Doppler echocardiography for the assessment of left ventricular diastolic function: methodology, clinical and prognostic value.  Ital Heart J Suppl. 2004;  5 86-97
• 27 Gaskari S A, Honar H, Lee S S. Therapy insight: cirrhotic cardiomyopathy.  Nat Clin Pract Gastroenterol Hepatol. 2006;  3 329-337
• 28 Alexander J, Mishra P, Desai N, Ambadekar S, Gala B, Sawant P. Cirrhotic cardiomyopathy: Indian scenario.  J Gastroenterol Hepatol. 2007;  22 395-399
• 29 Pozzi M, Carugo S, Boari G et al.. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites.  Hepatology. 1997;  26 1131-1137
• 30 Torregrosa M, Aguade S, Dos L et al.. Cardiac alterations in cirrhosis: reversibility after liver transplantation.  J Hepatol. 2005;  42 68-74
• 31 Bernardi M, Calandra S, Colantoni A et al.. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors.  Hepatology. 1998;  27 28-34
• 32 Kempler P, Szalay F, Váradi A et al.. Prolongation of the QTc-interval reflects the severity of autonomic neuropathy in primary biliary cirrhosis and in other non-alcoholic liver diseases.  Z Gastroenterol. 1993;  31(suppl 2) 96-98
• 33 Finucci G, Lunardi F, Sacerdoti D. Q-T interval prolongation in liver cirrhosis: reversibility after orthotopic liver transplantation.  Jpn Heart J. 1998;  39 321-329
• 34 Day C P, James O F, Butler T J, Campbell R W. QT prolongation and sudden cardiac death in patients with alcoholic liver disease.  Lancet. 1993;  341 1423-1428
• 35 Mohamed R, Forsey P R, Davies M K, Neuberger J M. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease.  Hepatology. 1996;  23 1128-1134
• 36 Bal J S, Thuluvath P J. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation.  Liver Int. 2003;  23 243-248
• 37 Trevisani F, Merli M, Savelli F et al.. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt.  J Hepatol. 2003;  38 461-467
• 38 Carey E J, Douglas D D. Effects of orthotopic liver transplantation on the corrected QT interval in patients with end-stage liver disease.  Dig Dis Sci. 2005;  50 320-323
• 39 Hansen S, Møller S, Bendtsen F, Jensen G, Henriksen J H. Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes.  J Hepatol. 2007;  , April 5 (Epub ahead of print)
• 40 Henriksen J H, Bendtsen F, Hansen E F, Møller S. Acute nonselective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis.  J Hepatol. 2004;  40 239-246
• 41 Zambruni A, Di Micoli A, Lubisco A, Domenicali M, Trevisani F, Bernardi M. QT interval correction in patients with cirrhosis.  J Cardiovasc Electrophysiol. 2007;  18 77-82
• 42 Henriksen J H, Fuglsang S, Bendtsen F, Christensen E, Moller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis.  J Hepatol. 2002;  36 513-520
• 43 Lee S S, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats.  Hepatology. 1990;  12 481-485
• 44 Inserte J, Perelló A, Agulló L et al.. Left ventricular hypertrophy in rats with biliary cirrhosis.  Hepatology. 2003;  38 589-598
• 45 Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis.  Clin Sci. 1999;  97 259-267
• 46 Keller H, Bezjak V, Stegaru B, Buss J, Holm E, Heene D L. Ventricular function in cirrhosis and portasystemic shunt: a two-dimensional echocardiographic study.  Hepatology. 1988;  8 658-662
• 47 Spatt S D, Rosenblatt P. The incidence of hypertension in portal cirrhosis: a study of 80 necropsied cases of portal cirrhosis.  Ann Intern Med. 1949;  31 479-483
• 48 Hall E M, Olsen A Y, Davis F E. Portal cirrhosis: clinical and pathologic review of 782 cases from 16,600 necropsies.  Am J Pathol. 1953;  29 993-1027
• 49 Lunseth J H, Olmstead E G, Abboud F. A study of heart disease in one hundred eight hospitalized patients dying with portal cirrhosis.  AMA Arch Intern Med. 1958;  102 405-413
• 50 Ocel J J, Edwards W D, Tazelaar H D, Petrovic L M, Edwards B S, Kamath P S. Heart and liver disease in 32 patients undergoing biopsy of both organs, with implications for heart or liver transplantation.  Mayo Clin Proc. 2004;  79 492-501
• 51 Silver M A, Maisel A, Yancy C W et al.. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.  Congest Heart Fail. 2004;  10(suppl 3) 1-30
• 52 Pateron D, Beyne P, Laperche T et al.. Elevated circulating cardiac troponin I in patients with cirrhosis.  Hepatology. 1999;  29 640-643
• 53 Wong F, Siu S, Liu P, Blendis L M. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?.  Clin Sci (Lond). 2001;  101 621-628
• 54 Yildiz R, Yildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients.  J Gastroenterol Hepatol. 2005;  20 1115-1120
• 55 Henriksen J H, Gotze J P, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.  Gut. 2003;  52 1511-1517
• 56 Zambruni A, Trevisani F, Gülberg V et al.. Daily profile of circulating C-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects: relationship with renal function.  Scand J Gastroenterol. 2007;  42 642-647
• 57 Milani A, Zaccaria R, Bombardieri G, Gasbarrini A, Pola P. Cirrhotic cardiomyopathy.  Dig Liver Dis. 2007;  39 507-515
• 58 Liu H, Song D, Lee S S. Cirrhotic cardiomyopathy.  Gastroenterol Clin Biol. 2002;  26 842-847
• 59 Myers R P, Lee S S. Cirrhotic cardiomyopathy and liver transplantation.  Liver Transpl. 2000;  6 S44-S52
• 60 Donovan C L, Marcovitz P A, Punch J D et al.. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation.  Transplantation. 1996;  61 1180-1188
• 61 Sampathkumar P, Lerman A, Kim B Y et al.. Post-liver transplantation myocardial dysfunction.  Liver Transpl Surg. 1998;  4 399-403
• 62 Therapondos G, Flapan A D, Plevris J N, Hayes P C. Cardiac morbidity and mortality related to orthotopic liver transplantation.  Liver Transpl. 2004;  10 1441-1453
• 63 Starzl T E, Demetris A J, Van Thiel D. Liver transplantation (2).  N Engl J Med. 1989;  321 1092-1099
• 64 Marquez J, Martin D, Virji M A et al.. Cardiovascular depression secondary to ionic hypocalcemia during hepatic transplantation in humans.  Anesthesiology. 1986;  65 457-461
• 65 Johnston S D, Morris J K, Cramb R, Gunson B K, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation.  Transplantation. 2002;  73 901-906
• 66 Park S C, Beerman L B, Gartner J C et al.. Echocardiographic findings before and after liver transplantation.  Am J Cardiol. 1985;  55 1373-1378
• 67 Nasraway S A, Klein R D, Spanier T B et al.. Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation: evidence for early postoperative myocardial depression.  Chest. 1995;  107 218-224
• 68 Piscaglia F, Zironi G, Gaiani S et al.. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study.  Hepatology. 1999;  30 58-64
• 69 Glauser F L. Systemic hemodynamic and cardiac function changes in patients undergoing orthotopic liver transplantation.  Chest. 1990;  98 1210-1215
• 70 Al-Hamoudi W, Alqahtani S, Ma M, Lee S S. Hemodynamics in the immediate postoperative period after liver transplantation in alcoholic and postviral cirrhosis [abstract].  Can J Gastroenterol. 2007;  21(suppl A) S029
• 71 Therapondos G, Flapan A D, Dollinger M M, Garden O J, Plevris J N, Hayes P C. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus.  Liver Transpl. 2002;  8 690-700
• 72 Acosta F, De La Morena G, Villegas M et al.. Evaluation of cardiac function before and after liver transplantation.  Transplant Proc. 1999;  31 2369-2370
• 73 Liu H, Lee S S. What happens to cirrhotic cardiomyopathy after liver transplantation?.  Hepatology. 2005;  42 1203-1205
• 74 Lee S S, Baik S K. Cardiovascular consequences of liver disease. In: Boyer TD, Wright T, Zakim MM Boyer's Hepatology: A Textbook of Liver Disease. 5th ed. Philadelphia, PA; WB Saunders Co Ltd 2006: 453-475
• 75 Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study.  Hepatology. 1994;  19 129-132
• 76 Rodriguez-Laiz J M, Banares R, Echenagusia A et al.. Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension: preliminary results.  Dig Dis Sci. 1995;  40 2121-2127
• 77 Quiroga J, Sangro B, Nunez M et al.. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters.  Hepatology. 1995;  21 986-994
• 78 Lotterer E, Wengert A, Fleig W E. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis.  Hepatology. 1999;  29 632-639
• 79 Braverman A C, Steiner M A, Picus D, White H. High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting.  Chest. 1995;  107 1467-1469
• 80 Huonker M, Schumacher Y O, Ochs A, Sorichter S, Keul J, Rössle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt.  Gut. 1999;  44 743-748
• 81 Ginès P, Uriz J, Calahorra B et al.. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.  Gastroenterology. 2002;  123 1839-1847
• 82 Schwartz J M, Beymer C, Althaus S J et al.. Cardiopulmonary consequences of transjugular intrahepatic portosystemic shunts: role of increased pulmonary artery pressure.  J Clin Gastroenterol. 2004;  38 590-594
• 83 Sanyal A J, Genning C, Reddy K R et al.. The North American Study for the Treatment of Refractory Ascites.  Gastroenterology. 2003;  124 634-641
• 84 Salerno F, Merli M, Riggio O et al.. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites.  Hepatology. 2004;  40 629-635
• 85 Cazzaniga M, Salerno F, Pagnozzi G et al.. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt.  Gut. 2007;  56 869-875
• 86 Lee S S, Liu H. Cardiovascular determinants of survival in cirrhosis.  Gut. 2007;  56 746-748
• 87 Ruiz-del-Arbol L, Urman J, Fernández J et al.. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis.  Hepatology. 2003;  38 1210-1218
• 88 Liu H, Lee S S. TNF-alpha in cirrhotic cardiomyopathy [abstract].  J Hepatol. 2002;  36(suppl 1) 11
• 89 Lee S S. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy?.  Hepatology. 2003;  38 1089-1091
• 90 Ruiz-del-Arbol L, Monescillo A, Arocena C et al.. Circulatory function and hepatorenal syndrome in cirrhosis.  Hepatology. 2005;  42 439-447
• 91 Le Grimellec C, Friedlander G, el Yandouzi E H, Zlatkine P, Giocondi M C. Membrane fluidity and transport properties in epithelia.  Kidney Int. 1992;  42 825-836
• 92 Lee R F, Glenn T K, Lee S S. Cardiac dysfunction in cirrhosis.  Best Pract Res Clin Gastroenterol. 2007;  21 125-140
• 93 Ma Z, Miyamoto A, Lee S S. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats.  Gastroenterology. 1996;  110 1191-1198
• 94 Ma Z, Meddings J B, Lee S S. Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats.  Am J Physiol. 1994;  267 G87-G93
• 95 Fernández-Rodriguez C M, Romero J, Petros T J et al.. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis.  Liver Int. 2004;  24 477-483
• 96 Ford W R, Honan S A, White R, Hiley C R. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts.  Br J Pharmacol. 2002;  135 1191-1198
• 97 Bonz A, Laser M, Kullmer S et al.. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle.  J Cardiovasc Pharmacol. 2003;  41 657-664
• 98 Gaskari S A, Liu H, Moezi L, Li Y, Baik S K, Lee S S. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.  Br J Pharmacol. 2005;  146 315-323
• 99 Liu H, Ma Z, Lee S S. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.  Gastroenterology. 2000;  118 937-944
• 100 Van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related.  J Hepatol. 1996;  24 747-752
• 101 Garcia-Estan J, Ortiz M C, Lee S S. Nitric oxide and renal and cardiac dysfunction in cirrhosis.  Clin Sci (Lond). 2002;  102 213-222
• 102 Liu H, Song D, Lee S S. Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat.  Am J Physiol Gastrointest Liver Physiol. 2001;  280 G68-G74
• 103 Cohen R A, Weisbrod R M, Gericke M, Yaghoubi M, Bierl C, Bolotina V M. Mechanism of nitric oxide-induced vasodilatation: refilling of intracellular stores by sarcoplasmic reticulum Ca2 + ATPase and inhibition of store-operated Ca2 + influx.  Circ Res. 1999;  84 210-219
• 104 Meissner G, Henderson J S. Rapid calcium release from cardiac sarcoplasmic reticulum vesicles is dependent on Ca^{2 +} and is modulated by Mg^{2 +} , adenine nucleotide, and calmodulin.  J Biol Chem. 1987;  262 3065-3073
• 105 Ward C A, Liu H, Lee S S. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy.  Gastroenterology. 2001;  121 1209-1218
• 106 O'Connor C M. The new heart failure guidelines: strategies for implementation.  Am Heart J. 2007;  153(suppl) 2-5
• 107 Pozzi M, Grassi G, Ratti L et al.. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral Child A cirrhosis.  Am J Gastroenterol. 2005;  100 1110-1116
• 108 Ward C A, Ma Z, Lee S S, Giles W R. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis.  Am J Physiol. 1997;  273 G537-G544